Skip to main content
Erschienen in: Reactions Weekly 1/2012

01.04.2012 | Case report

Belimumab

Drug hypersensitivity: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Excerpt

An event is serious (FDA MedWatch definition) when the patient outcome is:
  • death
  • life-threatening
  • hospitalisation
  • disability
  • congenital anomaly
  • requires intervention to prevent permanent impairment or damage
Literatur
1.
Zurück zum Zitat Berzanskis A, GSK.Direct Healthcare Professional Communication on the association of Benlysta (belimumab) with Hypersensitivity and Infusion reactions. Internet Document: [2 pages], 5 Mar 2012. Available from: URL: http://www.mhra.gov.uk/ - United Kingdom Berzanskis A, GSK.Direct Healthcare Professional Communication on the association of Benlysta (belimumab) with Hypersensitivity and Infusion reactions. Internet Document: [2 pages], 5 Mar 2012. Available from: URL: http://​www.​mhra.​gov.​uk/​ - United Kingdom
Metadaten
Titel
Belimumab
Drug hypersensitivity: case report
Publikationsdatum
01.04.2012
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2012
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.2165/00128415-201213960-00037

Weitere Artikel der Ausgabe 1/2012

Reactions Weekly 1/2012 Zur Ausgabe

Case report

Rituximab

Case report

Diphenhydramine

Case report

Vandetanib